Stay updated with breaking news from Mark Frattini. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell
NEW YORK, May 17, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data... | May 17, 2023
NEW YORK, May 17, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data... | June 12, 2023
BALLI-01 abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL populationNEW YORK, May 11, 2023 -- Cellectis , a clinical-stage biotechnology company... | May 11, 2023
UCART22 is currently the most advanced allogeneic CAR T-cell product in development for relapsed or refractory B-cell acute lymphoblastic leukemia The BALLI-01 study is actively enrolling patients... | April 11, 2023